Breast Cancer Clinical Trial Monitor — HER2, TNBC, HR+ & ADC Programs

The breast cancer trial landscape in 2026

Breast cancer is one of the most active oncology therapeutic areas. The ADC wave — following T-DXd and sacituzumab govitecan — has spawned dozens of follow-on programs across HER2 expression levels and TNBC. CDK4/6 inhibitor combinations continue expanding into earlier lines. PARP inhibitors are extending into BRCA-mutated early-stage settings.

For oncology-focused pharma and biotech professionals, keeping up with the breast cancer clinical trial pipeline manually is essentially impossible. New trials are posted continuously, and status changes happen daily.

Key programs and mechanisms to monitor

• HER2-positive: Next-generation anti-HER2 ADCs, bispecific antibodies, TKI combinations
• Triple-negative (TNBC): PD-1/PD-L1 combinations, TROP2 ADCs, PARP combinations in BRCA-mutated
• HR+ HER2-negative: CDK4/6 inhibitor combinations beyond approved settings, PI3K/AKT/mTOR targeting
• HER2-low: T-DXd successors and competitive ADC programs
• Early stage: Neoadjuvant and adjuvant programs, de-escalation trials
• Prevention: High-risk population studies, chemoprevention programs

Who uses breast cancer trial monitoring

Oncology business development teams

Companies in the breast cancer space track new competitive entries, Phase 2/3 transitions, and trial terminations to inform licensing decisions and competitive strategy. The ADC space alone has dozens of programs competing for similar patient populations.

Breast cancer patient advocacy organizations

Organizations like BCRF, Susan G. Komen, and disease-specific foundations use clinical trial awareness to connect patients to studies — especially patients with TNBC or metastatic disease who need options beyond standard of care.